Every finding in the evidence table: 382 rows, filterable

Every row

Filter

Area All 382 Care, carers and services 140 Medicines 85 Genes (not modifiable) 35 All modifiable factors together 27 Diet and supplements 23 Exercise and activity 21 Sleep, mood and social life 19 Hearing and vision 8 Alcohol, tobacco and cannabis 6 Infection and vaccination 5 Heart and metabolic health 4 Injury, delirium and falls 4 Environment 3 Cognitive activity 2

Question Both Prevention 190 Treatment 192

Direction Any Benefit 144 Harm 105 No effect 38 Mixed 37 No direction reported 58

Design Any meta-analysis 57 randomised trial 44 phase 3 trial 15 systematic review 9 phase 2 trial 10 cohort study 136 phase 1 trial 2 cross-sectional study 31 case-control study 14 modelling study 20 regulatory decision 7 company announcement 1 coverage determination 1 None 35

Showing 5 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 5 rows. Every row links to its source.
Exposure	Question	Direction	Outcome measured	Design	People	Effect size, as the source reported it	Source
APOE genotype Genes (not modifiable)	Prevention	Harm why Direction is for the APOE4 allele, whose effect ranged from OR 2.22 in Caribbean-Hispanic to 6.13 in Peruvian/Bolivian participants. The APOE2 allele went the other way (OR 0.81). Not modifiable.	Alzheimer's disease and related dementias (odds ratio)	case-control study	12,221	APOE ε4 meta-analytic OR 2.32 (95% CI 2.09-2.57); range 2.22 (Caribbean-Hispanics) to 6.13 (Peruvians/Bolivians)	Alzheimer's & Dementia 2025 ✓ Peer-reviewed PMID 40219824
APOE genotype Genes (not modifiable)	Prevention	Harm why Direction is for carrying APOE*4: the ε3/ε4 odds ratio fell stepwise from 4.54 in East Asian to 3.46 in White, 2.18 in Black and 1.90 in Hispanic individuals; ε2 was protective in White and Black but not Hispanic or East Asian individuals. Not modifiable.	Odds of Alzheimer's disease by APOE genotype, across ancestry, sex and age	case-control study	68,756	Odds ratios for APOE34 and AD risk attenuated following East Asian (OR, 4.54; 95% CI, 3.99-5.17),White (OR, 3.46; 95% CI, 3.27-3.65), Black (OR, 2.18; 95% CI, 1.90-2.49) and Hispanic (OR, 1.90; 95% CI, 1.65-2.18) individuals. Similarly, ORs for APOE22+23 and AD risk attenuated following White (OR, 0.53, 95% CI, 0.48-0.58), Black (OR, 0.69, 95% CI, 0.57-0.84), and Hispanic (OR, 0.89; 95% CI, 0.72-1.10) individuals	JAMA Neurology 2023 ✓ Peer-reviewed PMID 37930705
Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1) Genes (not modifiable)	Prevention	Harm why Direction is for carrying the African ancestry-specific APOE R145C variant with an ε3/ε4 genotype: three-fold higher odds of AD and onset about six years earlier in the discovery stage, replicated in stage 2 and concordant in stage 3. Not modifiable.	Alzheimer's disease case status and age at onset among APOE ε3/ε4 carriers of African ancestry	case-control study	31,929	R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10-6) and was associated with a reported younger age at AD onset (β, -5.87 years; 95% CI, -8.35 to -3.4 years; P = 3.4 × 10-6)	JAMA 2023 ✓ Peer-reviewed PMID 36809323
Anticholinergic / benzodiazepine burden Medicines	Treatment	Harm	180-day mortality	case-control study	139,103	180-day mortality HR 1.41 (95% CI 1.38-1.44) for benzodiazepines; HR 1.16 (95% CI 1.12-1.20) for antipsychotics	JAMA Network Open 2025 ✓ Peer-reviewed PMID 41085983
Antipsychotics (harms / discontinuation) Medicines	Treatment	Harm	180-day mortality	case-control study	139,103	180-day mortality HR 1.41 (95% CI 1.38-1.44) for benzodiazepines; HR 1.16 (95% CI 1.12-1.20) for antipsychotics	JAMA Network Open 2025 ✓ Peer-reviewed PMID 41085983

How this table was built, and where it is weak →

Every row of the evidence table

Every row